Dark

CCXI
Churchill Capital Corp XI Class A
stock NASDAQ

At Close

Feb 10, 2026 11:14:09 AM EST

10.23USD0.000%(0.00)4,743

0.00Bid 0.00Ask 0.00Spread

Pre-market

Feb 10, 2026 9:21:30 AM EST

10.26USD+0.293%(+0.03)115

After-hours

Feb 9, 2026 4:38:30 PM EST

10.45USD+1.852%(+0.19)0

Overview HistoricalExchangesShortsNews

Jan 19, 2022

02:39PM EST ChemoCentryx shares were trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis. Benzinga

08:40AM EST ChemoCentryx Reports EU Approval Of Co.'s TAVNEOS For Treatment Of ANCA-Associated Vasculitis; Launch Expected In H1'22 Benzinga

08:30AM EST ChemoCentryx Announces EU Approval of TAVNEOS GlobeNewswire Inc

Jan 4, 2022

Nov 12, 2021

08:42AM EST ChemoCentryx Announces Positive Recommendation For Use Of TAVNEOS In ANCA Vasculitis Adopted By European Medicines Agency Committee For Medicinal Products For Human Use Benzinga

08:30AM EST Positive Recommendation for Use of TAVNEOS GlobeNewswire Inc

Nov 10, 2021

12:17PM EST Expert Ratings For ChemoCentryx Benzinga

09:12AM EST Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to $110 Benzinga

08:00AM EST ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: GlobeNewswire Inc

Nov 9, 2021

05:34PM EST ChemoCentryx Q3 EPS $(0.32) Beats $(0.45) Estimate, Sales $17.74M Beat $13.48M Estimate Benzinga

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 8, 2021

09:58AM EST Earnings Preview For ChemoCentryx Benzinga

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 2, 2021

08:30AM EDT ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2021 to discuss these results and to answer questions. GlobeNewswire Inc

Oct 11, 2021

10:51AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021 Benzinga

10:13AM EDT Thinking About Buying Stock In Starbucks, Peloton Or ChemoCentryx? Benzinga

08:33AM EDT JP Morgan Upgrades ChemoCentryx to Neutral, Raises Price Target to $38 Benzinga

08:30AM EDT Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product GlobeNewswire Inc

07:46AM EDT SVB Leerink Upgrades ChemoCentryx to Outperform, Raises Price Target to $64 Benzinga

07:35AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:18AM EDT A Peek Into The Markets: US Stock Futures Down; Crude Oil Jumps 2% Benzinga

06:17AM EDT A Peek Into The Markets: US Stock Futures Drop Down; Crude Oil Jumps 2% Benzinga

04:47AM EDT Raymond James Upgrades ChemoCentryx to Strong Buy, Raises Price Target to $107 Benzinga

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 8, 2021

02:36PM EDT Mid-Afternoon Market Update: Dow Surges 80 Points; ChemoCentryx Shares Spike Higher Benzinga

01:16PM EDT UPDATE: Raymond James Upgrades ChemoCentryx from Outperform to Strong Buy, Raises Price Target from $62 to $107 Benzinga

12:30PM EDT Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge Benzinga

10:52AM EDT UPDATE: ChemoCentryx President Says 'We are encouraged by the data thus far, and intend to initiate a phase III trial in severe HS patients in early 2022 and discuss the C3G data with the FDA to determine a potential path forward.' Benzinga

10:52AM EDT EXCLUSIVE: ChemoCentryx President Thomas Schall On The Co's TAVNEOS FDA Approval Tells Benzinga 'We are ready for a fast launch ... and hope to make TAVNEOS available to clinicians and patients in the next few weeks.' Benzinga

10:27AM EDT Shares of ChemoCentryx Inc. (CCXI) surged 80% on Friday morning after the U.S. Food and Drug Administration approved the company's vasculitis drug. RTTNews

10:11AM EDT Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September Benzinga

09:01AM EDT Shares of ChemoCentryx Inc (CCXI) have risen more than 72 percent in pre-market trading Friday, following FDA approval of the company's Avacopan. RTTNews

07:32AM EDT ChemoCentryx Says FDA Approves Tavneos In ANCA-Associated RTTNews

07:14AM EDT ChemoCentryx: FDA Approves TAVNEOS For The Treatment Of ANCA-Associated Vasculitis RTTNews

07:04AM EDT ChemoCentryx Shares To Resume Trade At 7:30 a.m. EDT Benzinga

07:00AM EDT ChemoCentryx Reports FDA Approval Of Avacopan In Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Benzinga

07:00AM EDT -- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- GlobeNewswire Inc

06:58AM EDT BZ NOTE: Chemocentryx Halted Ahead Of Decision By FDA For Co.'s New Drug Application For Avacopan As Treatment For Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Benzinga

06:55AM EDT Chemocentryx Shares Halted News Pending Benzinga

06:51AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 6.30 A.M. EDT). RTTNews

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 5, 2021

09:17AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 5, 2021: RIDE, RL, CCXI, ANVS, PROG Benzinga

Oct 3, 2021

02:21PM EDT The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More Benzinga

Oct 1, 2021

02:29PM EDT Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates Benzinga

Sep 27, 2021

08:54AM EDT ChemoCentryx Announces Approval Of TAVNEOS In Japan - RTTNews

08:36AM EDT ChemoCentryx Announces Approval Of TAVNEOS In Japan For ANCA-Associated Vasculitis RTTNews

08:32AM EDT ChemoCentryx Announces Approval In Japan Of TAVNEOS For Treatment Of ANCA-Associated Vasculitis Benzinga

08:30AM EDT ChemoCentryx Announces Approval in Japan of GlobeNewswire Inc

Sep 13, 2021

12:57PM EDT ChemoCentryx's Return On Capital Employed Overview Benzinga

Sep 2, 2021

08:30AM EDT ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: GlobeNewswire Inc

Aug 9, 2021

05:36PM EDT ChemoCentryx: Q2 Earnings Insights Benzinga

05:26PM EDT ChemoCentryx Q3 EPS $(0.56) Down From $(0.35) YoY Benzinga

04:05PM EDT -- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021-- GlobeNewswire Inc

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

08:30AM EDT ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11 at 5:00 p.m. ET. GlobeNewswire Inc

Aug 2, 2021

06:10PM EDT Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates Benzinga

08:30AM EDT ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2021 to discuss these results and to answer questions. GlobeNewswire Inc

Jul 26, 2021

01:08PM EDT ChemoCentryx Option Alert: Oct 15 $20 Calls at the Ask: 1629 @ $2.951 vs 301 OI; Earnings 8/9 After Close [est] Ref=$14.6 Benzinga

Jul 7, 2021

11:14PM EDT Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. (ChemoCentryx or the Company) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

11:41AM EDT Analyst Ratings For ChemoCentryx Benzinga

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2021 Benzinga

08:22AM EDT (CCXI Long-Term Investor Alert: Did You Acquire ChemoCentryx Before November PR Newswire

07:53AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

05:06AM EDT Stifel Upgrades ChemoCentryx to Buy, Raises Price Target to $31 Benzinga

Jul 6, 2021

03:20PM EDT Why This ChemoCentryx Analyst Is Bullish Benzinga

09:18AM EDT ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7 Benzinga

09:02AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Jul. 6, 2021: CCXI, DIDI, AXP, ADXS, OGI Benzinga

08:43AM EDT ChemoCentryx Files Amendment To NDA Submission And Extends PDUFA Review Period For Avacopan To Oct 7 RTTNews

08:35AM EDT ChemoCentryx Shares Tick Higher; Co Announces Filing Of Amendment To NDA Submission, Extension Of The PDUFA Review Period For Avacopan In Treatment Of ANCA-Associated Vasculitis Benzinga

08:30AM EDT ChemoCentryx Announces Filing of Amendment to NDA Submission and GlobeNewswire Inc

Jul 5, 2021

11:37PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:09PM EDT SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI PR Newswire

10:10AM EDT Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for ChemoCentryx, PR Newswire

Jul 4, 2021

12:19PM EDT CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

Jul 2, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

10:50PM EDT CHEMOCENTRYX 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against ChemoCentryx, Inc. - CCXI Business Wire

Jun 30, 2021

10:13PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

06:46PM EDT Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts GlobeNewswire Inc

Jun 29, 2021

11:35PM EDT CCXI Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or PR Newswire

11:34PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

Jun 28, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

04:17PM EDT Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. (ChemoCentryx or the Company) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

09:50AM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

Jun 25, 2021

10:50PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

10:20AM EDT Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & GlobeNewswire Inc

Jun 23, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

04:15PM EDT Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. (CCXI) PR Newswire

Jun 22, 2021

11:14PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

01:46PM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

Jun 21, 2021

10:39PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

01:38PM EDT Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

Jun 18, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 17, 2021

11:50AM EDT of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. (CCXI) PR Newswire

09:06AM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

Jun 16, 2021

10:33PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

08:19PM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action GlobeNewswire Inc

08:30AM EDT ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on Wednesday, June 23 at 10:40 a.m. ET. GlobeNewswire Inc

Jun 15, 2021

11:11PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

Jun 14, 2021

10:54PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 12, 2021

02:11PM EDT Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

11:05AM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

Jun 11, 2021

10:00PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:35AM EDT Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class PR Newswire

Jun 10, 2021

04:45PM EDT to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel PR Newswire

Jun 9, 2021

09:37PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 8, 2021

10:40PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

05:27PM EDT Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. (ChemoCentryx or the Company) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

05:10PM EDT CCXI CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

08:30AM EDT -- Abstract on The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease honored on Ten Best list by the Paper Selection Committee of ERA-EDTA -- GlobeNewswire Inc

Jun 7, 2021

10:57PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

03:02PM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

Jun 4, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

10:50AM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action GlobeNewswire Inc

Jun 2, 2021

11:28PM EDT Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. (ChemoCentryx or the Company) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

09:56PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 1, 2021

10:00PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

May 31, 2021

10:31PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

01:08PM EDT CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces GlobeNewswire Inc

May 30, 2021

11:52AM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against PR Newswire

May 28, 2021

May 27, 2021

08:45PM EDT CCXI Alert: Did You Buy ChemoCentryx Public Offering Shares in June 2020? PR Newswire

May 26, 2021

10:43PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

09:04PM EDT Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. (ChemoCentryx or the Company) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

10:00PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

12:27PM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

May 24, 2021

10:46PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:30AM EDT CCXI ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities PR Newswire

May 23, 2021

03:10PM EDT Kessler Topaz Meltzer & Check, LLP Reminds ChemoCentryx, Inc. GlobeNewswire Inc

May 21, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 20, 2021

10:04PM EDT Pomerantz LLP is investigating claims on behalf of investors of ChemoCentryx, Inc. (ChemoCentryx or the Company) (NASDAQ: CCXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

12:16PM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

May 19, 2021

03:09PM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action GlobeNewswire Inc

May 18, 2021

10:51PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

06:20PM EDT CCXI INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline PR Newswire

May 17, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 15, 2021

03:25PM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

May 14, 2021

01:46PM EDT Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

May 12, 2021

09:49PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

08:30PM EDT Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of PR Newswire

May 11, 2021

10:44PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 10, 2021

11:21PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

07:07PM EDT ChemoCentryx, Inc. Class Action Reminder: Kessler Topaz Meltzer & GlobeNewswire Inc

02:39PM EDT Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. A securities fraud class action is pending and certain investors may have valuable claims. GlobeNewswire Inc

May 7, 2021

10:45PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

03:03PM EDT Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop Benzinga

12:20PM EDT Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April Benzinga

10:17AM EDT Analysts React To FDA AdCom Vote On ChemoCentryx's Avacopan, Stock Plunges Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021 Benzinga

09:35AM EDT CCXI INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to PR Newswire

08:48AM EDT 10 Biggest Price Target Changes For Friday Benzinga

07:42AM EDT Raymond James Downgrades ChemoCentryx to Outperform, Lowers Price Target to $51 Benzinga

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

07:38AM EDT SVB Leerink Downgrades ChemoCentryx to Market Perform, Lowers Price Target to $17 Benzinga

07:05AM EDT Stifel Downgrades ChemoCentryx to Hold, Lowers Price Target to $26 Benzinga

06:49AM EDT HC Wainwright & Co. Maintains Buy on ChemoCentryx, Lowers Price Target to $28 Benzinga

06:47AM EDT Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate Benzinga

06:46AM EDT ChemoCentryx AdCom Panel Results For Avacopan Out Late Thursday: Panel Voted 10-8 In Favor Of Approval Benzinga

06:46AM EDT ChemoCentryx Shares To Resume Trade At 7:10 a.m. EDT Benzinga

06:44AM EDT JP Morgan Downgrades ChemoCentryx to Underweight, Lowers Price Target to $17 Benzinga

06:44AM EDT Hearing ChemoCentryx AdCom Panel Results For Avacopan: Panel Voted 10-8 In Favor Of Approval Benzinga

06:43AM EDT Piper Sandler Downgrades ChemoCentryx to Neutral, Lowers Price Target to $25 Benzinga

May 6, 2021

01:02PM EDT CCXI CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a PR Newswire

10:15AM EDT ChemoCentryx Shares Resume Halted With Code News Pending; Stock Halted Ahead Of FDA AdCom Panel; FDA Meeting Commencing Soon Benzinga

09:51AM EDT ChemoCentryx Files For Patent Titled 'HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES' Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

03:58PM EDT ChemoCentryx Option Alert: May 21 $40 Calls Sweep (7) near the Ask: 200 @ $2.301 vs 1137 OI; Ref=$27.27 Benzinga

12:12PM EDT ChemoCentryx Shares Quiet; Canaccord Issues Note Titled 'Confusing briefing documents create a constructive setup into tomorrow's AdCom, as data address many of FDA's concerns' Benzinga

09:35AM EDT Investors with Losses to Contact Its Attorneys Now, FDA Briefing Document Raises Serious Questions, Firm Investigating Possible Securities Law Violations PR Newswire

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

03:31PM EDT ChemoCentryx Shares See Volume; Canaccord Genuity Issues Note Titled 'Briefing docs for Thursday's AdCom miss big picture, but ChemoCentryx is prepared to support avacopan in AAV with data' Benzinga

01:19PM EDT ChemoCentryx Stock Plunges As FDA Briefing Document Casts Doubt On Vasculitis Candidate Avacopan's Data Benzinga

10:51AM EDT Raymond James Maintains Strong Buy On ChemoCentryx Benzinga

10:50AM EDT UPDATE: Raymond James On ChemoCentryx: 'The hepatic AE tox discussion is more serious than we expected which after first pass through the docs is maybe our biggest concern' Benzinga

10:50AM EDT UPDATE: Raymond James On ChemoCentryx: 'Stock is justifiably down but in the end we do expect the committee to conclude benefits outweight risks.' Benzinga

10:49AM EDT Raymond James On ChemoCentryx FDA Briefing Doc For Avacopan: 'The materials are more critical than we expected, and reveal a fairly high bar FDA set for ADVOCATE. FDA is questioning both efficacy and safety' Benzinga

10:28AM EDT UPDATE: FDA Briefing Doc For ChemoCentryx's Avacopan Shows Candidate 'is an efficacious treatment for patients with this rare disease and fulfills unmet medical needs for this patient population,' Benefits Outweigh Risks Benzinga

10:25AM EDT UPDATE: FDA Briefing Doc For ChemoCentryx Shows 'superiority was not met using investigator assessed score' Benzinga

10:25AM EDT Mid-Morning Market Update: Markets Open Lower; Pfizer Raises FY21 Outlook Benzinga

Apr 29, 2021

05:11PM EDT Recap: ChemoCentryx Q1 Earnings Benzinga

04:33PM EDT ChemoCentryx Q1 EPS $(0.43) Misses $(0.40) Estimate, Sales $10.35M Beat $7.93M Estimate Benzinga

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 22, 2021

08:30AM EDT ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on April 29, 2021 to discuss these results and to answer questions. GlobeNewswire Inc

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 9, 2021

08:31AM EDT ChemoCentryx Says Co's Oral PD-L1 Inhibitor CCX559, Featured In Poster Presentation At 2021 American Association For Cancer Research Annual Meeting Benzinga

08:30AM EDT -- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- GlobeNewswire Inc

Apr 7, 2021

08:30AM EDT ChemoCentryx to Host Virtual R&D Day on April 14, 2021 GlobeNewswire Inc

Mar 8, 2021

08:47AM EST ChemoCentryx Appoints Susan Kanaya To Board RTTNews

08:47AM EST ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Companys Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. GlobeNewswire Inc

Mar 2, 2021

01:16PM EST Stifel Initiates Coverage On ChemoCentryx with Buy Rating, Announces Price Target of $93 Benzinga

07:20AM EST Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to $120 Benzinga

Mar 1, 2021

04:30PM EST ChemoCentryx: Q4 Earnings Insights Benzinga

04:21PM EST ChemoCentryx Q4 EPS $(0.43) Misses $(0.33) Estimate, Sales $4.36M Miss $7.99M Estimate Benzinga

04:05PM EST -- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 25, 2021

Feb 24, 2021

08:38AM EST ChemoCentryx Appoints Tausif Butt As EVP And COO RTTNews

08:30AM EST -- Brings more than two decades of executive management experience from global pharmaceutical companies -- GlobeNewswire Inc

Feb 23, 2021

08:30AM EST ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after market close on Monday, March 1, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2021 to discuss these results and to answer questions. GlobeNewswire Inc

Feb 17, 2021

05:01PM EST ChemoCentryx Highlights Publication In New England Journal Of Medicine Of Results Of Pivotal Phase 3 ADVOCATE Trial Of Avacopan For Treatment Of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Benzinga

05:00PM EST -- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- GlobeNewswire Inc

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 8, 2021

11:01AM EST Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to $119 Benzinga

Jan 6, 2021

08:30AM EST ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.: GlobeNewswire Inc

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 21, 2020

04:09PM EST ChemoCentryx and VFMCRP Provide Topline Results From ACCOLADE Trial Of Avacopan In C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate Benzinga

04:05PM EST ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE GlobeNewswire Inc

Nov 19, 2020

Nov 10, 2020

11:28AM EST ChemoCentryx shares were trading lower after the company reported worse-than-expected Q3 EPS and sales results. Benzinga

Nov 9, 2020

05:01PM EST Recap: ChemoCentryx Q3 Earnings Benzinga

04:20PM EST ChemoCentryx Q3 EPS $(0.35) Misses $(0.31) Estimate, Sales $5.08M Miss $10.70M Estimate Benzinga

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 6, 2020

10:15AM EST Earnings Outlook For ChemoCentryx Benzinga

08:34AM EST ChemoCentryx Announces Plenary Session At ACR Convergence 2020 To Highlight Findings Of ADVOCATE Phase III Trial In ANCA-Associated Vasculitis Benzinga

08:30AM EST -- Study Showed Treatment with AvacopanAchieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal Function Compared to the Prednisone Group -- GlobeNewswire Inc

Nov 3, 2020

08:31AM EST ChemoCentryx, VFMCRP Report EMA Accepts For Review Marketing Authorization Application For Avacopan Benzinga

08:30AM EST -- Companies have completed the EU regulatory applicationfor marketing approval of avacopan -- Regulatory submission based on positive data from the pivotal Phase-III ADVOCATE trial of avacopan GlobeNewswire Inc

Nov 2, 2020

08:30AM EST ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after market close on Monday, November 9, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2020 to discuss these results and to answer questions. GlobeNewswire Inc

Oct 29, 2020

12:07PM EDT Why ChemoCentryx's Stock Is Trading Lower Today Benzinga

09:54AM EDT Wells Fargo Maintains Overweight on ChemoCentryx, Lowers Price Target to $70 Benzinga

09:32AM EDT Benzinga's Top Upgrades, Downgrades For October 29, 2020 Benzinga

09:16AM EDT Piper Sandler Maintains Overweight on ChemoCentryx, Raises Price Target to $71 Benzinga

08:27AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

05:59AM EDT JP Morgan Downgrades ChemoCentryx to Neutral, Lowers Price Target to $60 Benzinga

05:04AM EDT SVB Leerink Maintains Outperform on ChemoCentryx, Raises Price Target to $84 Benzinga

Oct 28, 2020

04:07PM EDT ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS) Benzinga

04:01PM EDT -- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at 12 weeks; numerical improvement observed with avacopan treatment in overall study population -- GlobeNewswire Inc

Oct 22, 2020

03:47PM EDT 'Fast Money Halftime Report' Picks For October 22 Benzinga

Sep 17, 2020

08:35AM EDT ChemoCentryx Announces FDA Acceptance Of The Avacopan New Drug Application For The Treatment Of ANCA-Associated Vasculitis Benzinga

08:30AM EDT ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug GlobeNewswire Inc

Sep 8, 2020

08:30AM EDT ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C.Wainwright22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30 p.m. ET. GlobeNewswire Inc

Aug 11, 2020

08:00AM EDT Raymond James Maintains Strong Buy on ChemoCentryx, Raises Price Target to $100 Benzinga

Aug 10, 2020

04:08PM EDT ChemoCentryx Q2 EPS $0.29 Up From $(0.26) YoY, Sales $49.44M Up From $7.17M YoY Benzinga